Compare Bristol-Myers Squibb Co (BMY) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ABRDN Physical Gold Shares ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.58 (market cap $116.30B), while ABRDN Physical Gold Shares ETF trades at $38.7. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while ABRDN Physical Gold Shares ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SGOL | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $51.41 |
52-Week Low | $42.60 | $31.18 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SGOL is trading at $38.1, down 2.61% amid broader gold market weakness. The technical picture shows bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. Gold ETFs face headwinds from rising Treasury yields and Federal Reserve policy uncertainty, though central bank buying provides underlying support. Recent CPI data provided temporary relief but failed to sustain momentum.
The outlook remains cautious as gold faces competing forces - supportive central bank demand versus restrictive monetary policy. Near-term direction hinges on Fed policy clarity and inflation trends, with technical resistance at $39-$40 levels posing immediate challenges for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
